Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Establish the Safety and Tolerability of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

NCT00950638 is registered in ClinicalTrials.gov with Ophthotech Corporation as lead sponsor.

NCT NCT00950638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00950638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Establish the Safety and Tolerability of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
Lead sponsor
Ophthotech Corporation
Phase
Phase 1
Overall status
Completed
Start date
July 16, 2009
Completion date
March 24, 2011
Enrollment
47 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dry age-related macular degeneration